Septic

EQS-News: AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock

Retrieved on: 
Wednesday, April 10, 2024
Sepsis, Communication, Patient, Public, Fast Track, Adrenomedullin, Biomarker, Accelerated approval (FDA), Mortality, Septic shock, Death, DPP3, Septic, Medicine, Priority review, Organ dysfunction, Intensive care medicine, CMO, Collection, FDA, Infection, RCI, Food, Pharmaceutical industry

AdrenoMed is now preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.

Key Points: 
  • AdrenoMed is now preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.
  • AdrenoMed’s CEO Dr. Richard Jones commented: “We are very pleased that enibarcimab has received Fast Track designation from the FDA, recognizing its potential as an innovative biomarker-guided treatment against septic shock to fill the unmet medical need in this very serious condition with a high death toll.
  • With a mortality rate of 20-30% for sepsis [1] and 30%-50% for septic shock in developed countries, [2] sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths worldwide.
  • Dr. Stephan Witte, CMO of AdrenoMed, said: “We are very confident that the use of enibarcimab in combination with two biomarkers, Adrenomedullin (bio-ADM) and circulating dipeptidyl peptidase 3 (cDPP3), holds the promise to become the first effective targeted treatment against septic shock.

Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Round

Retrieved on: 
Thursday, February 22, 2024
Blood pressure, Blood, School, Sepsis, Woman, IIA, Bleeding, Doctor of Philosophy, Resuscitation, The, Shock, MD, Diarrhea, Temperature, Septic, University, Nitric oxide, Shock (mechanics), Senior advisor, Finger, Life, Urinary tract infection, Risk, Internal bleeding, Pelvic floor dysfunction, Malaria, Hypovolemia, Nanoparticle, Gangrene, Neonatal sepsis, JD, Patient, Septic shock, Clinical trial, UMKC, Child, Reperfusion injury, Hypotension, Partnership

Targeted $20M Series B Round to include Sub-Saharan Africa in product development.

Key Points: 
  • Targeted $20M Series B Round to include Sub-Saharan Africa in product development.
  • Vivacelle Bio is partnering with Propelevate to drive the Sub-Saharan Africa strategy, which is fully integrated into its Series B financing round.
  • Through partnership with Propelevate, Vivacelle Bio will engage global health funders and stakeholders during final stages of product development, and Propelevate will drive Vivacelle Bio's go-to-market strategy for African markets upon regulatory approval.
  • "We are excited to partner with Vivacelle Bio because of their commitment to Sub-Saharan Africa.

Vital’s Scientific Publication on Sepsis Paves Way for Predictive Analytics Tools

Retrieved on: 
Monday, January 29, 2024
Technology, Mobile, Wireless, Health, Professional Services, Artificial Intelligence, Research, Software, Hospitals, Data Analytics, Internet, Health Technology, Science, Data Management, Clinical Trials, Artificial intelligence, Family, Septic, Patient, Natural language processing, Intuit Mint, Manuscript, Hospital, NLP, JMIR, Documentation, Workload, ED, AI, Sepsis, Algorithm, Patient satisfaction, Growth, AUC, Journal, Medicine, Machine learning, Triage, Physician, ROI

The peer-reviewed paper, " Sepsis Prediction at Emergency Department Triage Using Natural Language Processing: Retrospective Cohort Study ," highlights the power of artificial intelligence (AI) in predicting sepsis at the earliest stages.

Key Points: 
  • The peer-reviewed paper, " Sepsis Prediction at Emergency Department Triage Using Natural Language Processing: Retrospective Cohort Study ," highlights the power of artificial intelligence (AI) in predicting sepsis at the earliest stages.
  • Timely sepsis prediction: The research demonstrates that ML algorithms can accurately predict sepsis at ED presentation, enabling healthcare providers to intervene promptly and enhance patient care.
  • Sepsis was accurately predicted in 76% of septic patients where sepsis screening was not initiated at triage and 98% of cases where sepsis screening was initiated at triage.
  • To coincide with this publication, Vital is announcing future plans to deliver solutions that use predictive analytics to notify physicians and staff about quality and safety issues.

ECONSE HELPS ROUND TABLE BREWERY LAUNCH WITH ON-SITE, SUSTAINABLE, WASTEWATER TREATMENT

Retrieved on: 
Thursday, January 11, 2024
Environment, Hudson Valley, Septic, Nutrient, Water, Beer, Growth

LOCKPORT, N.Y., Jan. 11, 2024 /PRNewswire/ -- The Hudson Valley, while a beautiful region, has the unfortunate honor of having some of the most polluted water in the country. Instead of being part of the problem or waiting for further regulations, Round Table Brewery opened with clean and sustainable business practices right from the start. To meet their wastewater goals, they called on Econse for innovative technologies that empower them to minimize expenses, reduce environmental impact, and grow sustainably.

Key Points: 
  • Instead of being part of the problem or waiting for further regulations, Round Table Brewery opened with clean and sustainable business practices right from the start.
  • To meet their wastewater goals, they called on Econse for innovative technologies that empower them to minimize expenses, reduce environmental impact, and grow sustainably.
  • "Operating sustainably certainly isn't the simplest choice, but in our mind it was the only choice," says Ricardo Petroni, of Round Table Brewery.
  • Round Table Brewery has big plans for future growth, and the BrüClean System is able to grow with them.

NV5 Awarded $5 Million Contract to Improve Wastewater Collection in California

Retrieved on: 
Wednesday, January 3, 2024
Groundwater, Quality of life, Septic, Water, Environment, Sewage treatment

NV5 will serve as the owner’s representative for Phases 2 and 3 of the Hi-Desert Water District’s septic-to-sewer project.

Key Points: 
  • NV5 will serve as the owner’s representative for Phases 2 and 3 of the Hi-Desert Water District’s septic-to-sewer project.
  • NV5 will also deliver expertise in design review, environmental compliance support, grant funding assistance, and construction management and inspection services.
  • "Water treatment systems improve quality of life and positively impact the environment by reducing surface water pollution and recharging groundwater supplies.
  • NV5 is pleased to contribute to this project which will improve water infrastructure for Hi-Desert Water District customers while enhancing the community’s environmental sustainability," said Dickerson Wright, PE, Chairman and CEO of NV5.

New Study Underscores Need for Greater Objectivity and Speed in Sepsis Diagnosis and Triage

Retrieved on: 
Wednesday, December 6, 2023
Septic, Protocol, Sepsis, SAN, Emergency, Risk, ED, Patient, Pharmacy, Probability, Research, FDA, Emergency medicine, University, Diagnosis, Hospital medicine, Nursing care plan, Judgement, Infection, Hospital, Lehigh Valley Health Network, Triage, Medical imaging, Medical device, Nursing

SAN FRANCISCO, Dec. 6, 2023 /PRNewswire/ -- Cytovale® today announced the publication of a new peer-reviewed study that highlights the need for its IntelliSep® test. The study, published in "Journal of Personalized Medicine," examined healthcare provider assessments of patients' sepsis risk, which have implications on diagnosis and timely, appropriate care for this fast-moving, potentially deadly condition. The study also evaluated the impact of improved diagnostic tools, such as host response assays, in the emergency department (ED) to aid in the rapid diagnosis and risk stratification of those with suspected sepsis.

Key Points: 
  • The study, published in "Journal of Personalized Medicine," examined healthcare provider assessments of patients' sepsis risk, which have implications on diagnosis and timely, appropriate care for this fast-moving, potentially deadly condition.
  • About 80% of sepsis patients present to the ED , therefore there is a need for improved diagnostic tools , such as host response assays.
  • The study showed great potential for faster diagnosis, triage and treatment of sepsis when using host response assay tools, like the recently FDA-cleared IntelliSep test from Cytovale.
  • The case presentations and questions used in the study were developed by an independent steering committee, which also conducted the analysis.

Cytovale Secures $84 Million Series C to Advance Commercialization of Transformative Sepsis Diagnostic Tool

Retrieved on: 
Wednesday, November 15, 2023
Septic, Attention, Sepsis, SAN, GHIC, Risk, ED, Patient, End organ damage, Probability, FDA, Partner, Norwest Venture Partners, MD, Infection, Death, Splenic infarction, Hospital, Mechanics, Face, Triage, Pharmaceutical industry, Nursing, Vaccine

SAN FRANCISCO, Nov. 15, 2023 /PRNewswire/ -- Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced it has raised $84 million in Series C funding led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health Investment Corporation (GHIC). The financing included participation from other new and existing investors, as well as the conversion of bridge notes. Cytovale will use the proceeds to bring its recently FDA-cleared rapid sepsis diagnosis test – IntelliSep® – to more hospital emergency departments (ED) and health systems in the United States, addressing historical diagnosis lag time that makes sepsis the leading cause of death in U.S. hospitals.

Key Points: 
  • "Sepsis is a dangerous, fast-moving condition that can result in death if not identified and treated quickly," said Cytovale CEO Ajay Shah.
  • "Our flagship diagnostic tool, IntelliSep, with a blood-to-answer time frame of under 10 minutes, helps healthcare providers recognize sepsis early and make critical, time-sensitive clinical decisions.
  • Sepsis is the leading cause of death in U.S. hospitals, with more than one-third of all in-hospital deaths attributed to the condition.
  • About 80% of sepsis patients present to the ED , where it can be difficult to discern from ordinary infections or other conditions that can mimic sepsis.

Fapon, LASCCO, Abionic Formed Strategic Collaboration for PSP Sepsis Diagnosis in China

Retrieved on: 
Thursday, October 26, 2023
PSP, Survival, Patient, FDA, Research, C-reactive protein, Organ dysfunction, Fatigue, IVD, Biomarker, Ophthalmology, Septic shock, Immunoassay, Physician, Mortality, Septic, Obstetrics, IVDR, CE, Infection, Incidence, POC, Nausea, Metabolism, CLIA, Sepsis, Fever, Acute inhalation injury, Disease, Peritonitis, Medicine, Partnership, Burn, Neurology, Blood, Chills, CRP, Pain, Diagnosis, Death, Trauma, ICU, Medical imaging, Pharmaceutical industry, Silviculture, Hospital

This strategic partnership will usher in a significant breakthrough in the medical field, removing barriers to early sepsis diagnosis.

Key Points: 
  • This strategic partnership will usher in a significant breakthrough in the medical field, removing barriers to early sepsis diagnosis.
  • Performing PSP testing on high-risk individuals can flag potential sepsis before the onset of clinical symptoms.
  • However, these methods cannot meet the clinical needs for early diagnosis of sepsis as they have major limitations.
  • Obtaining the PSP license for the diagnosis of sepsis will further enhance Fapon's potential for innovative applications in the diagnosis of infectious diseases.

The American Water Security Project and Partners Applaud Florida TaxWatch's Septic-to-Sewer: Protecting Florida's Ground and Surface Water Report

Retrieved on: 
Tuesday, October 10, 2023
Environmental protection, Vibrio vulnificus, Multimedia, American Society of Civil Engineers, Sewage, Florida Department of Environmental Protection, Florida TaxWatch, Tourism, Society, Florida Legislature, American Water, Legislation, Septic, Florida Department, Executive, Biophysical environment, SELF, Water, Sewage treatment, Property insurance

ST PETERSBURG, Fla., Oct. 10, 2023 /PRNewswire/ -- The American Water Security Project, the Angler Action Foundation, and the Solar Energy Loan Fund applaud the release of Florida TaxWatch's Septic-to-Sewer: Protecting Florida's Ground and Surface Water Report. The report outlines four commonsense recommendations to combat the threat to Florida's waters by antiquated septic tank technologies:

Key Points: 
  • ST PETERSBURG, Fla., Oct. 10, 2023 /PRNewswire/ -- The American Water Security Project, the Angler Action Foundation, and the Solar Energy Loan Fund applaud the release of Florida TaxWatch's Septic-to-Sewer: Protecting Florida's Ground and Surface Water Report .
  • The Florida Department of Environmental Protection should work with the Florida Legislature to pass legislation that incorporates the provisions of Executive Order 23-06 into Florida Statutes.
  • Again, we congratulate Florida TaxWatch for a job well done and the Florida executive and legislative branches for taking Florida's water quality issues seriously.
  • The American Water Security Project is a registered 501(c)3.

LeapFrog Design Secures $500k in EPA Funding for Onsite Septic Treatment and Reuse

Retrieved on: 
Thursday, October 5, 2023
Public, Nitrogen, Water quality, LeapFrog Enterprises, Flushing, Carbon, United States Environmental Protection Agency, Water pollution, Entrepreneurship, Coral, EPA, Septic, Blackwater, Heat, Water, Sewage treatment

BEND, Ore., Oct. 5, 2023 /PRNewswire/ -- LeapFrog Design , pioneer in nature-based water treatment and reuse solutions, has been awarded $500,000 in funding from the Environmental Protection Agency (EPA).

Key Points: 
  • BEND, Ore., Oct. 5, 2023 /PRNewswire/ -- LeapFrog Design , pioneer in nature-based water treatment and reuse solutions, has been awarded $500,000 in funding from the Environmental Protection Agency (EPA).
  • LeapFrog will use the funding to adapt its proven greywater reuse technology for onsite septic treatment and reuse.
  • This EPA funding will help the company adapt that technology to also address blackwater — water from toilets, kitchen sinks, and dishwashers.
  • We're thankful to the EPA for funding our work to help solve this and many other water scarcity issues."